Leading the Way in Life Science Technologies

GEN Exclusives

More »

Wall Street BioBeat

More »

For full access to this article login to GEN Select now.

Jan 1, 2014 (Vol. 34, No. 1)

Asthma Prescription Numbers Slow Down

Monoclonal Antibodies Lead the Pipeline in the Development of Novel Therapeutics

  • The asthma prescription market is slowing as the leading drugs lose patent protection. But leading market researchers BCC and GBI Research each predict moderate ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »